Observational studyBreast (Edinburgh, Scotland)2026
Treatment patterns and clinical outcomes according to PD-L1 status in >2000 patients with early-stage or metastatic triple-negative breast cancer treated in the real-world setting: VANESSA study results.
Observational study in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of PD-L1 combined positive score with disease control and response kinetics with first-line pembrolizumab-based therapy in metastatic triple-negative breast cancer: results from routine clinical practice in Poland.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic effect of PD-L1 status in triple-negative breast cancer (TNBC) is uncertain and little is known about PD-L1-positive prevalence and outcomes in the real-world setting. PATIENTS AND
methodsThe multicentre retrospective observational VANESSA study evaluated the prevalence and impact of PD-L1-positive status in 2054 patients receiving systemic therapy for early-stage or metastatic (e/m)TNBC between 2014 and 2017. PD-L1 expression was assessed locally and centrally on archival samples. Descriptive analyses of demographic and clinicopathological characteristics, treatment patterns and clinical outcomes (extracted from patients' medical records) according to PD-L1 status were prespecified.
resultsAmong 1902 patients with eTNBC, 681 (36%) received neoadjuvant chemotherapy and 1261 (66%) adjuvant chemotherapy. Demographic characteristics were generally similar regardless of PD-L1 status, but lower-risk tumour characteristics were more common in the PD-L1-positive subgroup. Invasive disease-free and overall survival were more favourable in PD-L1-positive eTNBC. In the mTNBC cohort, 120/145 (83%) patients had de novo mTNBC. Median progression-free survival on first-line treatment was 7.6 months (95% CI: 4.1-15.0) in PD-L1-positive mTNBC (n = 30) and 4.9 months (95% CI: 3.6-6.1) in PD-L1-negative mTNBC (n = 83).
conclusionIn eTNBC and mTNBC, PD-L1-positive status was associated with more favourable long-term outcomes, possibly due to tumour-intrinsic characteristics and/or the host immune response. The high proportion with de novo mTNBC may suggest enrolment bias and/or geographic variations in stage at diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.